Drug Profile

Itacitinib - Incyte Corporation

Alternative Names: IBI-377; INCB-039110; INCB-039110-adipate; INCB-39110; Itacitinib-adipate

Latest Information Update: 13 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Incyte Corporation
Developer ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP); AstraZeneca; H. Lee Moffitt Cancer Center and Research Institute; Incyte Corporation; Innovent Biologics; National Cancer Institute (USA); University of Utah
Class Acetonitriles; Anti-inflammatories; Antianaemics; Antibronchitics; Antineoplastics; Antipsoriatics; Antirheumatics; Azetidines; Fluorocarbons; Piperidines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
Mechanism of Action Janus kinase 1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Graft-versus-host disease
New Molecular Entity Yes

Phase II Cytokine release syndrome; Diffuse large B cell lymphoma; Diffuse scleroderma; Haemophagocytic lymphohistiocytosis; Hodgkin's disease; Immunological disorders; Myelofibrosis; Non-small cell lung cancer
Phase I/II Bronchiolitis obliterans; Haematological malignancies; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours
No development reported Aplastic anaemia; Graft-versus-host disease; Liver cancer; Malignant melanoma; Soft tissue sarcoma; T-cell prolymphocytic leukaemia
Discontinued Pancreatic cancer; Plaque psoriasis; Rheumatoid arthritis

24 Jun 2026 Incyte Corporation terminates phase II trial in Myelofibrosis (Combination therapy, Monotherapy, Second-line therapy or greater) in USA (PO) due to the expiration of remaining drug supply (NCT04640025)
26 Feb 2026 Incyte Corporation completes a phase I trial in Hodgkin's disease and Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT01905813)
06 Dec 2025 Efficacy and adverse event data from the phase II HLH-JAK trial presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com